protein restriction slows the progression of kidney disease delaying the dialysis treatment. The cost of treatment of end-stage renal disease is high and increases with age. Therefore, delaying the start of renal replacement therapy with hemodialysis and improving the patient's quality of life are two primary goals justifying the use of protein-restricted diets. The aim of the study was to evaluate the economic impact of a low-protein diet (0.6 gr proteins/kg, body weight/day) with the intent of delay the haemodialysis treatment in patients with advanced chronic-renalfailure. METHODS: The study was a naturalistic, longitudinal retrospective Cost of Treatment study. Patients were enrolled during the 2005 and followed up until 2007 or the beginning of haemodialysis treatment. Direct health care resources attributable to disease management (drugs, ambulatory care, day case treatments, hospitalizations, specialist visits, diagnostics and laboratory exams) were quantified using National Health Service (NHS) tariffs expressed in Euro 2008. NHS perspective was adopted. Health-related quality of life information were also collected using SF-36 questionnaire at the enrolment and at the end of the observation period. RESULTS: We enrolled 30 patients (males 60%, mean age of 56.5 Ϯ 13.9 y.o.) from the Nephrology Department of the University "Federico II" of Naples, with a mean follow-up of 12.7 Ϯ 7.5 months. The average monthly cost of care was €1075.6 Ϯ 925.2 per patient, mainly because of hospitalization which represented the 45.0% of the expenses. SF-36 results showed a quality of life stable during the observation period and quite similar to the general population. CONCLUSIONS: This is the first study evaluating the economic impact of law-protein diet in patients with CRF in Italy. The protein-restricted diets helps to delay initiation of hemodialysis sessions, which substantially increase treatment costs and negatively impacts quality of life. The aim of this study was to assess the costeffectiveness of solifenacin (5 mg/10 mg) relative to tolterodine ER 4 mg in the treatment of patients with overactive bladder (OAB), from the perspective of the UK (NHS) health care system. METHODS: This was a cost-utility analysis based on a one-year decision-tree model. A systematic review and meta-analysis of efficacy data was performed to obtain estimates for clinical effectiveness. The benefits of treatment were measured according to resolution of OAB symptoms and subsequent improvement in health-related quality of life (HRQoL). Treatment success was defined separately for urgency, frequency and incontinence. Definitions of treatment success were no urge episodes, eight or fewer micturitions and no incontinence episodes per 24 hours respectively. Incremental cost-effectiveness ratios (ICERs) were estimated separately for each symptom. HRQoL values were taken from published sources. Treatment persistence data and data for the proportion of solifenacin patients receiving the higher dose, 10-mg formulation were obtained from the DIN-LINK database. The analysis was undertaken from the perspective of the UK NHS and included costs directly associated with the treatment of OAB, i.e. cost of antimuscarinics, GP consultations and consultations in an outpatient clinic; cost data was taken from NHS published sources (at 2007/2008 prices The aim of this study was to assess the costeffectiveness of solifenacin (5 mg/10 mg) relative to fesoterodine (4 mg/8 mg) for OAB, from the perspective of the UK (NHS) health care system. METHODS: A cost-utility analysis was undertaken using a one-year decision-tree model. Estimates for clinical effectiveness were obtained from a systematic review and meta-analysis. Treatment success was defined separately for urgency, frequency and incontinence. Definitions of treatment success were no urgency episodes, eight or fewer micturitions and no incontinence episodes per 24 hours. Incremental costeffectiveness ratios (ICERs) were estimated separately for each symptom. Treatment persistence rates for solifenacin and the percentage of patients requiring the higher-dose formulation of solifenacin were taken from the DIN-LINK database. In the absence of these data for fesoterodine, in the base case analysis treatment persistence and the percentage of patients requiring the higher dose formulation of fesoterodine were assumed to be equal to that for solifenacin. Utility values for the calculation of Quality Adjusted Life Years (QALYs) were taken from published sources. The analysis included costs directly associated with OAB treatment, i.e. antimuscarinic therapy, GP consultations and outpatient contacts; cost data were taken from NHS published sources (2007/2008 prices). Resource utilisation was based on expert opinion. RESULTS: In the base-case analysis, solifenacin resulted in a cost-effective treatment strategy compared with fesoterodine for urgency and frequency outcomes being both more effective and less costly. Fesoterodine was more effective but more expensive than solifenacin for incontinence, with an ICER of £84,686/QALY. CONCLUSIONS: This analysis suggests that fesoterodine does not provide a cost-effective treatment option relative to solifenacin at a cost-effectiveness threshold of £30,000/QALY for the resolution of urgency, frequency and incontinence in patients treated for OAB. 
PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MG VERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)
The aim of this study was to assess the costeffectiveness of solifenacin (5 mg/10 mg) relative to tolterodine ER 4 mg in the treatment of patients with overactive bladder (OAB), from the perspective of the UK (NHS) health care system. METHODS: This was a cost-utility analysis based on a one-year decision-tree model. A systematic review and meta-analysis of efficacy data was performed to obtain estimates for clinical effectiveness. The benefits of treatment were measured according to resolution of OAB symptoms and subsequent improvement in health-related quality of life (HRQoL). Treatment success was defined separately for urgency, frequency and incontinence. Definitions of treatment success were no urge episodes, eight or fewer micturitions and no incontinence episodes per 24 hours respectively. Incremental cost-effectiveness ratios (ICERs) were estimated separately for each symptom. HRQoL values were taken from published sources. Treatment persistence data and data for the proportion of solifenacin patients receiving the higher dose, 10-mg formulation were obtained from the DIN-LINK database. The analysis was undertaken from the perspective of the UK NHS and included costs directly associated with the treatment of OAB, i.e. cost of antimuscarinics, GP consultations and consultations in an outpatient clinic; cost data was taken from NHS published sources (at 2007/2008 prices The aim of this study was to assess the costeffectiveness of solifenacin (5 mg/10 mg) relative to fesoterodine (4 mg/8 mg) for OAB, from the perspective of the UK (NHS) health care system. METHODS: A cost-utility analysis was undertaken using a one-year decision-tree model. Estimates for clinical effectiveness were obtained from a systematic review and meta-analysis. Treatment success was defined separately for urgency, frequency and incontinence. Definitions of treatment success were no urgency episodes, eight or fewer micturitions and no incontinence episodes per 24 hours. Incremental costeffectiveness ratios (ICERs) were estimated separately for each symptom. Treatment persistence rates for solifenacin and the percentage of patients requiring the higher-dose formulation of solifenacin were taken from the DIN-LINK database. In the absence of these data for fesoterodine, in the base case analysis treatment persistence and the percentage of patients requiring the higher dose formulation of fesoterodine were assumed to be equal to that for solifenacin. Utility values for the calculation of Quality Adjusted Life Years (QALYs) were taken from published sources. The analysis included costs directly associated with OAB treatment, i.e. antimuscarinic therapy, GP consultations and outpatient contacts; cost data were taken from NHS published sources (2007/2008 prices) . Resource utilisation was based on expert opinion. RESULTS: In the base-case analysis, solifenacin resulted in a cost-effective treatment strategy compared with fesoterodine for urgency and frequency outcomes being both more effective and less costly. Fesoterodine was more effective but more expensive than solifenacin for incontinence, with an ICER of £84,686/QALY. CONCLUSIONS: This analysis suggests that fesoterodine does not provide a cost-effective treatment option relative to solifenacin at a cost-effectiveness threshold of £30,000/QALY for the resolution of urgency, frequency and incontinence in patients treated for OAB.
PUK13 EXPANDED CRITERIA DONORS IN RENAL TRANSPLANTATION: RESULTS OF ECONOMIC EVALUATION
Ortega T, Ortega F, Baltar JM,Valdés C, Diaz-Corte C, Gómez E Hospital Universitario Central de Asturias, Oviedo, Spain OBJECTIVES: At present, expanded criteria donors suppose up to 40-50% of the renal transplant. The aim was to evaluate cost-utility difference between standard criteria donors (SCD) versus expanded criteria donors (ECD) at the first year of kidney transplant. METHODS: Patients were collected in the waitinglist for renal transplant in our region from January 1, 2003 to December 31, 2005. Clinical and demographic variables, transplant costs and EQ-5D tariff, as a generic perceived state of Abstracts A653 health (PSH) profile, were analyzed. RESULTS: A total of 131 patients were included in the waiting-list and 80% received a kidney transplant, 41% were ECD. Sixty percent were men. The age difference between ECD, SCD and not transplanted was significant (p = 0.000). The mean time in waiting-list (15 months) and cold ischemia time (14 hours) were the same for both groups. There were no differences in clinical variables. The PSH improvement in ECD at year was significant (p = 0.022), whereas for the SCD not. There were differences in incomes (p = 0.041) between groups. The survival at first year was 100% for SCD and 97.7% for ECD. At year, mean cost for SCD transplant was €54,343/year versus €59.13€/year for ECD (no significant). The difference in QALYs between transplanted ones and not-transplanted was significant (p = 0.019). The utility was: 0.8096 QALYs for SCD, 0.7786 for ECD and 0.6838 for not transplanted. Cost-utility analysis showed that one QALY in SCD cost €67.27€, versus €79.95€/QALY of ECD and €80.43€/QALY of not transplanted in waiting list. CONCLUSIONS: There were no clinical differences and not in PSH at the first transplant year between SCD and ECD, but there were in age and what it bears. The differences in terms of cost-utility, in the first year, between ECD and not transplanted were small. However, the differences could be important in long term, because after the first year the costs have an important decrease. Therefore, it seems that ECD transplant have a good results in health and costs. ® and Neorecormon(r), respectively. There were no demographic differences between the treatment arms. There were no statistically significant differences between the 3 ESAs in the total annual anaemia management cost in haemodialysis treated chronic renal failure patients despite differences in drug list prices between the 3 ESAs. The cost ranged from €8203 to €9281. There were no significant differences in the average weekly dose of ESA between the 3 drugs. Independent of the iron status of the patient, or when stratified by CRP level, the percentage of patients reaching a Hb level Ն 11 g/dl was similar in the 3 treatment arms and ranged from 76% to 81%. CONCLUSIONS: In patients with chronic renal failure, treated with haemodialysis, there were no significant differences between the 3 available ESAs in medical resource use, average dose of ESA needed, annual anaemia management costs from the perspective of the Belgian public health care payer and in Hb control.
PUK14 A HEALTH ECONOMIC EVALUATION OF THE USE OF ERYTHROPOIESIS-STIMULATING AGENTS (ESA) IN PATIENTS WITH RENAL FAILURE TREATED WITH HAEMODIALYSIS

